Biocon Limited

rs,

, 2026 To, The Secretary BSE Limited Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, To, The Secretary National

7%

ue R & D % of Revenue EBITDA Q4 FY26 Q4 FY25 Q3 FY26 YoY% QoQ% 2,756 2,463 2,497 188 7% 720 153 6% 540 173 7% 700 12 23 33 10 9 3 o Yesintek traction continues, remains mark

6%

f Revenue EBITDA Q4 FY26 Q4 FY25 Q3 FY26 YoY% QoQ% 2,756 2,463 2,497 188 7% 720 153 6% 540 173 7% 700 12 23 33 10 9 3 o Yesintek traction continues, remains market leader amon

26%

33 10 9 3 o Yesintek traction continues, remains market leader among biosimilars % of Revenue 26% 22% 28% Europe: Stable, Tender-led Execution o Stable execution across oncology, immunology and

22%

0 9 3 o Yesintek traction continues, remains market leader among biosimilars % of Revenue 26% 22% 28% Europe: Stable, Tender-led Execution o Stable execution across oncology, immunology and opht

28%

3 o Yesintek traction continues, remains market leader among biosimilars % of Revenue 26% 22% 28% Europe: Stable, Tender-led Execution o Stable execution across oncology, immunology and ophthalmo

12%

Revenue R & D % of Revenue Financial Performance – Mix Driven Margin Strength o 4Q Revenues up 12% YoY, led primarily by North America market EBITDA 2,751 3,028 % of Revenue 26% 34% o 4Q EBIT

3,028 %

en Margin Strength o 4Q Revenues up 12% YoY, led primarily by North America market EBITDA 2,751 3,028 % of Revenue 26% 34% o 4Q EBITDA up 33% YoY, 26% EBITDA margin * Adjusted for BFI divestment gain

34%

evenues up 12% YoY, led primarily by North America market EBITDA 2,751 3,028 % of Revenue 26% 34% o 4Q EBITDA up 33% YoY, 26% EBITDA margin * Adjusted for BFI divestment gain in Q1FY25 FY25 (Ex-

33%

led primarily by North America market EBITDA 2,751 3,028 % of Revenue 26% 34% o 4Q EBITDA up 33% YoY, 26% EBITDA margin * Adjusted for BFI divestment gain in Q1FY25 FY25 (Ex-BFI divestment gai

13%

U.S. and for Tacrolimus across Latin American markets Financial Performance o 4Q Revenues grew 13% YoY, excluding one-time, generic lenalidomide sales in 4QFY25 – driven primarily by gLiraglutide

₹75 crore

lenalidomide sales in 4QFY25 – driven primarily by gLiraglutide launches in Europe o 4Q EBITDA at ₹75 crore; EBITDA margin at 8% improved nearly 300 basis points QoQ o Margins reflect higher costs from re